Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients (NCT07051629)
A Phase 1, Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIF001 in Healthy Subjects and in a Patient Cohort With Epilepsy
🩺 Plain-English Summary (8th-Grade Level)
This is a dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SIF001, a monoclonal antibody with the potential to treat epilespy
Who can join: Review the eligibility criteria below.
Location: Center for Neurosciences — Tucson, Arizona
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- Center for Neurosciences — Tucson, Arizona
- Accel Research sites network — DeLand, Florida
- D&H Tamarac Research Center, LLC — Tamarac, Florida
- Encore Medical Research of Weston, LLC — Weston, Florida
- Hawaii Pacific Neuroscience, Comprehensive Epilepsy Center — Honolulu, Hawaii
- Mid-Atlantic Epilepsy and Sleep Center — Bathesda, Maryland
- Quest Research Institute — Farmington Hills, Michigan
- Dent Neurologic Institute — Amherst, New York
- OnSite Clinical Solutions, LLC — Charlotte, North Carolina
- Horizon Clinical Research Center — Cypress, Texas
📞 Contact the Study Coordinator
Phone: (650) 785-0225
Email: dsun@suninflam.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Epilepsy
- Neural Circulatory Control and SUDEP Risk. — Rochester, Minnesota
- BHV-7000 Responsive Neurostimulation System (RNS) Study — New Haven, Connecticut
- RESEARCH EVALUATING VAGAL EXCITATION AND ANATOMICAL LINKS — Stanford, California
- Acute Recording of Stereotyped High-Frequency Oscillations — Rochester, Minnesota
- Neurophysiologically Based Brain State Tracking and Modulation in Focal Epilepsy — Rochester, Minnesota
- Acoustic Stimulation for Seizure Suppression — New York, New York
Explore by condition: All Epilepsy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.